NOV 05, 2020 7:00 AM PST

Awakening Ancient DNA to Kill Cancer

WRITTEN BY: Tara Fernandez

In a recent study published in Nature, scientists from the University of Toronto described the discovery of ancient DNA within our genomes with immense hidden powers. These elements, which have been conserved over the course of humans’ evolutionary history, have the ability to trigger powerful immune responses, strong enough to eliminate cancer cells.

Daniel De Carvalho, a senior author of the study explained: “Humans acquired a series of ‘silent’ repetitive elements in our DNA over millions of years of evolution, but it has been unclear why or what purpose they serve.”

“As ‘genome archeologists,’ we set out to identify the function of these DNA relics and have found that under the right conditions they can be reactivated and stimulate our immune system.” 

These so-called DNA relics are SINEs, or Short Interspersed Nuclear Elements, repetitive DNA sequences that typically lie dormant in a state of inactivity. Pharmaceutical agents known as epigenetic drugs, however, are the key to awakening these elements, which in turn set off the generation of double-stranded RNA. 

The body interprets this flood of double-stranded DNA as a red flag signaling infection and calls for immediate innate immune system backup — which includes a flood of potentially cancer-killing immune pathways.

The immune system’s task of getting rid of cancerous cells, however, is an uphill battle. Tumors use a variety of sneaky strategies to evade capture, including the production of ADAR1: an enzyme that blocks SINEs’ double-stranded RNA from activating immune responses.

“Since the ADAR1 activity is enzymatic, our work provides an exciting new target for drug development efforts for a completely new class of drugs that could exploit these ancient weapons in our genome,” said De Carvalho. In the study, the team showed that removing the tumor’s ability to produce ADAR1 made them more susceptible to killing by the body’s immune responses.

 

 

Sources: University of Toronto, Nature.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 12, 2021
Cell & Molecular Biology
A Molecule From the Gut Microbiome May Fight Tumors
JUL 12, 2021
A Molecule From the Gut Microbiome May Fight Tumors
The more we learn abut the gut microbiome, the more it seems that the microorganisms in our gastrointestinal tracts can ...
JUL 15, 2021
Immunology
Your Immune System Can't Deal With All the Plastic You're Eating
JUL 15, 2021
Your Immune System Can't Deal With All the Plastic You're Eating
Microplastics—tiny fragments of plastic, less than five millimeters in diameter—pollute our environment and, ...
JUL 22, 2021
Immunology
"Stunning" Anti-Inflammatory Effects of a Fermented Food Diet
JUL 22, 2021
"Stunning" Anti-Inflammatory Effects of a Fermented Food Diet
Researchers at Stanford University have found that consuming fermented foods such as yogurt, sauerkraut, and kombucha te ...
AUG 24, 2021
Immunology
Women Produce More COVID Antibodies Than Men
AUG 24, 2021
Women Produce More COVID Antibodies Than Men
An exploration into the human immune response after a COVID-19 infection has revealed a surprising finding: women produc ...
AUG 31, 2021
Health & Medicine
People Who Have Had SARS-CoV-2 Infection Have Longer-Lasting Immunity Than Those Who Were Vaccinated Only
AUG 31, 2021
People Who Have Had SARS-CoV-2 Infection Have Longer-Lasting Immunity Than Those Who Were Vaccinated Only
Consider yourself among the luckiest if you made a full recovery from infection with SARS-CoV-2, especially if you were ...
SEP 21, 2021
Immunology
1 in 5 Hospitalized COVID Patients Develop Self-Destructive Antibodies
SEP 21, 2021
1 in 5 Hospitalized COVID Patients Develop Self-Destructive Antibodies
One in five hospitalized COVID-19 patients go on to develop autoantibodies—immune molecules that mistakenly target ...
Loading Comments...